Search research articles
Contact Us
Filters
Showing results (21-30 of 67) with videos related to
Page
of 7
Sort By:
BMC Cancer
|
March 28, 2026
Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma
Patric Ejder, Henrik Jespersen, Micaela Hernberg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Cancer Management and Research
|
November 29, 2023
Characteristics of Real-World Patients with High-Risk <i>BRAF</i><sup>V600E/K</sup>-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program
Pietro Quaglino, Paolo A Ascierto, Francesca Consoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Journal for Immunotherapy of Cancer
|
November 18, 2020
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study
Piotr Rutkowski, Alice Indini, Matilde De Luca, et al.
The Lancet. Oncology
|
April 18, 2025
Clinical validation of droplet digital PCR assays in detecting BRAF<sup>V600</sup>-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Mahrukh M Syeda, Georgina V Long, James Garrett, et al.
Journal for Immunotherapy of Cancer
|
July 3, 2023
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
Kohei Shitara, Maria Di Bartolomeo, Mario Mandala, et al.
Journal for Immunotherapy of Cancer
|
March 30, 2021
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 12, 2018
MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium
Alexander J Stratigos, Maria Concetta Fargnoli, Arcangela De Nicolo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 67) with videos related to
Sort By:
Page
of 7
BMC Cancer
|
March 28, 2026
Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma
Patric Ejder, Henrik Jespersen, Micaela Hernberg, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 6, 2020
Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Cancer Management and Research
|
November 29, 2023
Characteristics of Real-World Patients with High-Risk <i>BRAF</i><sup>V600E/K</sup>-Mutated Melanoma Receiving Adjuvant Treatment with Dabrafenib Plus Trametinib After Surgical Resection, Through the Italian Managed Access Program
Pietro Quaglino, Paolo A Ascierto, Francesca Consoli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2023
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of <i>BRAF</i>-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
Paolo A Ascierto, Reinhard Dummer, Helen J Gogas, et al.
Journal for Immunotherapy of Cancer
|
November 18, 2020
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study
Piotr Rutkowski, Alice Indini, Matilde De Luca, et al.
The Lancet. Oncology
|
April 18, 2025
Clinical validation of droplet digital PCR assays in detecting BRAF<sup>V600</sup>-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Mahrukh M Syeda, Georgina V Long, James Garrett, et al.
Journal for Immunotherapy of Cancer
|
July 3, 2023
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
Kohei Shitara, Maria Di Bartolomeo, Mario Mandala, et al.
Journal for Immunotherapy of Cancer
|
March 30, 2021
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
Maria Gonzalez-Cao, Teresa Puertolas, Mar Riveiro, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
August 12, 2018
MelaNostrum: a consensus questionnaire of standardized epidemiologic and clinical variables for melanoma risk assessment by the melanostrum consortium
Alexander J Stratigos, Maria Concetta Fargnoli, Arcangela De Nicolo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2019
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
Helen J Gogas, Keith T Flaherty, Reinhard Dummer, et al.
Page
of 7